Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer

[1]  M. Zhang,et al.  Identification of aberrant promoter methylation of EDNRB gene in esophageal squamous cell carcinoma. , 2009, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[2]  Pei‐Ching Hsiao,et al.  Promoter methylation of p16 and EDNRB gene in leukemia patients in Taiwan. , 2008, The Chinese journal of physiology.

[3]  G. Kristiansen,et al.  The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation , 2008, Oncogene.

[4]  Y. Liu,et al.  Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cells. , 2007, Human pathology.

[5]  F. Spinella,et al.  ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo , 2007, Molecular Cancer Therapeutics.

[6]  M. Smollich,et al.  The endothelin axis: a novel target for pharmacotherapy of female malignancies. , 2007, Current Vascular Pharmacology.

[7]  M. Grimshaw.  Endothelins and hypoxia-inducible factor in cancer. , 2007, Endocrine-related cancer.

[8]  M. Esteller.  Epigenetic gene silencing in cancer: the DNA hypermethylome. , 2007, Human molecular genetics.

[9]  J. Brooks,et al.  Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. , 2007, Cancer letters.

[10]  J. Nelson,et al.  Endothelin receptor A blockade enhances taxane effects in prostate cancer. , 2006, Neoplasia.

[11]  I. McKillop,et al.  Bosentan® inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis , 2006, Clinical & Experimental Metastasis.

[12]  Christian Pilarsky,et al.  Molecular Profiling of Laser-Microdissected Matched Tumor and Normal Breast Tissue Identifies Karyopherin α2 as a Potential Novel Prognostic Marker in Breast Cancer , 2006, Clinical Cancer Research.

[13]  G. Kristiansen,et al.  Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis , 2006, Oncogene.

[14]  Errol M. Thomson,et al.  Pulmonary Expression of PreproET-1 and PreproET-3 mRNAs Is Altered Reciprocally in Rats After Inhalation of Air Pollutants , 2006, Experimental biology and medicine.

[15]  Pen-Hui Yin,et al.  Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan. , 2006, Oncology reports.

[16]  F. Spinella,et al.  Emerging role of the endothelin axis in ovarian tumor progression. , 2005, Endocrine-related cancer.

[17]  L. Trümper,et al.  Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. , 2005, DNA and cell biology.

[18]  Javed Khan,et al.  Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers , 2005, Clinical Cancer Research.

[19]  Matthew J Grimshaw,et al.  Endothelins in breast tumour cell invasion. , 2005, Cancer letters.

[20]  S. Gelling,et al.  Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer , 2005, The Journal of pathology.

[21]  Gangning Liang,et al.  Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer Patients , 2004, Clinical Cancer Research.

[22]  Joanna H Shih,et al.  Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways , 2004, Oncogene.

[23]  Irina Klaman,et al.  Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. , 2004, International journal of oncology.

[24]  P. Natali,et al.  Endothelin receptors as novel targets in tumor therapy , 2004, Journal of Translational Medicine.

[25]  T. Hagemann,et al.  A Role for Endothelin-2 and Its Receptors in Breast Tumor Cell Invasion , 2004, Cancer Research.

[26]  Jeanne Kowalski,et al.  Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer , 2004, Cancer Research.

[27]  Wei Dong Chen,et al.  Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer , 2004, Nature Genetics.

[28]  L. Kiesel,et al.  Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  L. Larue,et al.  Involvement of endothelin receptors in normal and pathological development of neural crest cells. , 2003, The International journal of developmental biology.

[30]  J. Nelson,et al.  The endothelin axis: emerging role in cancer , 2003, Nature Reviews Cancer.

[31]  P. Natali,et al.  Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. , 2002, Cancer research.

[32]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[33]  S. Burchill,et al.  Endothelins may modulate invasion and proliferation of Ewing's sarcoma and neuroblastoma. , 2002, Clinical science.

[34]  F. Spinella,et al.  Endothelin-1 Induces Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1α in Ovarian Carcinoma Cells* , 2002, The Journal of Biological Chemistry.

[35]  J. Nelson,et al.  Endothelin-1 as a Target for Therapeutic Intervention in Prostate Cancer , 2002, Investigational New Drugs.

[36]  J. Kwong,et al.  Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma , 2002, International journal of cancer.

[37]  H. Moch,et al.  Tissue microarray (TMA) technology: miniaturized pathology archives for high‐throughput in situ studies , 2001, The Journal of pathology.

[38]  G. Liang,et al.  The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. , 2001, Human molecular genetics.

[39]  Chakrabarti,et al.  Augmented expression of endothelin‐1, endothelin‐3 and the endothelin‐B receptor in breast carcinoma , 2000, Histopathology.

[40]  Rainer M. Bohle,et al.  Real-time quantitative RT–PCR after laser-assisted cell picking , 1998, Nature Medicine.

[41]  K. Catt,et al.  Endothelins as Autocrine Regulators of Tumor Cell Growth , 1998, Trends in Endocrinology & Metabolism.

[42]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Magnuson,et al.  Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. , 1996, Cancer research.

[44]  B. Levin.  Book Review Cancer Prevention and Control (Basic and Clinical Oncology.) Edited by Peter Greenwald, Barnett S. Kramer, and Douglas L. Weed. 803 pp. New York, Marcel Dekker, 1995. $195. 0-8247-9258-0 , 1995 .

[45]  R. W. Janes,et al.  A comparison of X‐ray and NMR structures for human endothelin‐1 , 1995, Protein science : a publication of the Protein Society.

[46]  C. Mitaka,et al.  Effects of TNF-alpha on hemodynamic changes and circulating endothelium-derived vasoactive factors in dogs. , 1994, The American journal of physiology.

[47]  I. Ellis,et al.  Method for grading breast cancer. , 1993, Journal of clinical pathology.

[48]  G. Rubanyi,et al.  Endothelins , 1991, The Lancet.

[49]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.

[50]  M. Chou,et al.  Aberrant promoter methylation of EDNRB in lung cancer in Taiwan. , 2006, Oncology reports.

[51]  T. Masaki.  The endothelin family: an overview. , 2000, Journal of cardiovascular pharmacology.

[52]  A. Ortega Mateo,et al.  Highlights on endothelins: a review. , 1997, Pharmacological research.

[53]  E. Levin.  Mechanisms of disease : endothelins , 1995 .

[54]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.